Before the clinical introduction of targeted therapies, cytokine-based immunotherapy with interleukin-2 (IL-2) and/or interferon-alfa (IFN-α) was the standard therapy for stage IV RCC (Table 1). This evidence concerns the gene IL2 and renal cell carcinoma.